Compare AJANTA PHARMA with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PLETHICO PHARMA AJANTA PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 23.5 -1.1 - View Chart
P/BV x 4.1 0.0 24,728.6% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 AJANTA PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
PLETHICO PHARMA
Mar-14
AJANTA PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422395 360.1%   
Low Rs89831 2,867.7%   
Sales per share (Unadj.) Rs233.5604.4 38.6%  
Earnings per share (Unadj.) Rs44.032.5 135.4%  
Cash flow per share (Unadj.) Rs52.251.3 101.6%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.1473.6 53.9%  
Shares outstanding (eoy) m88.0234.08 258.3%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.00.4 1,408.6%   
Avg P/E ratio x26.46.6 402.1%  
P/CF ratio (eoy) x22.24.2 535.6%  
Price / Book Value ratio x4.50.5 1,010.3%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,0817,262 1,405.6%   
No. of employees `0006.8NA-   
Total wages/salary Rs m4,3071,596 269.9%   
Avg. sales/employee Rs Th3,022.6NM-  
Avg. wages/employee Rs Th633.4NM-  
Avg. net profit/employee Rs Th569.1NM-  
INCOME DATA
Net Sales Rs m20,55420,598 99.8%  
Other income Rs m211386 54.6%   
Total revenues Rs m20,76520,984 99.0%   
Gross profit Rs m5,6642,818 201.0%  
Depreciation Rs m721642 112.2%   
Interest Rs m121,593 0.7%   
Profit before tax Rs m5,143969 531.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273-138 -919.9%   
Profit after tax Rs m3,8701,107 349.6%  
Gross profit margin %27.613.7 201.5%  
Effective tax rate %24.8-14.3 -173.2%   
Net profit margin %18.85.4 350.4%  
BALANCE SHEET DATA
Current assets Rs m11,81218,877 62.6%   
Current liabilities Rs m3,77611,896 31.7%   
Net working cap to sales %39.133.9 115.4%  
Current ratio x3.11.6 197.1%  
Inventory Days Days7736 215.3%  
Debtors Days Days82198 41.2%  
Net fixed assets Rs m14,3989,861 146.0%   
Share capital Rs m175341 51.5%   
"Free" reserves Rs m22,27712,331 180.7%   
Net worth Rs m22,45216,139 139.1%   
Long term debt Rs m74,706 0.1%   
Total assets Rs m26,96233,146 81.3%  
Interest coverage x444.31.6 27,634.6%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.80.6 122.7%   
Return on assets %14.48.1 176.7%  
Return on equity %17.26.9 251.3%  
Return on capital %23.012.3 186.7%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m10,6824,402 242.6%   
Fx outflow Rs m2,1023,184 66.0%   
Net fx Rs m8,5801,219 704.1%   
CASH FLOW
From Operations Rs m3,7482,437 153.8%  
From Investments Rs m-2,228-6,265 35.6%  
From Financial Activity Rs m-1,4752,490 -59.2%  
Net Cashflow Rs m45-1,337 -3.4%  

Share Holding

Indian Promoters % 73.8 82.7 89.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.3 36.0%  
FIIs % 7.6 5.5 138.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 7.5 226.7%  
Shareholders   20,968 10,665 196.6%  
Pledged promoter(s) holding % 4.4 85.7 5.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - ALEMBIC LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS